Navigation Links
Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
Date:5/17/2013

RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference (ATS 2013) in Philadelphia, PA, May 17 – 22. Data will highlight research conducted with a product approved for the treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium bromide inhalation powder)], as well as investigational compounds for asthma, idiopathic pulmonary fibrosis (IPF) and COPD.

The breadth of Boehringer Ingelheim data at ATS 2013, one of the largest gatherings of pulmonary clinicians and researchers in the world, reinforces the company's commitment to lung health and to finding solutions for physicians and patients where unmet needs exist.

Boehringer Ingelheim's abstracts in respiratory research can be accessed through the ATS website, http://conference.thoracic.org. The data will remain under embargo until the date and time that the data are presented (details below).

Tiotropium (Investigational)
Tiotropium is being investigated to determine its efficacy and safety in treating patients with asthma and is not approved for this indication.Title Lead
Author Presentation Details Tiotropium In Asthma: A
Dose-Finding Study In Adult
Patients With Moderate
Persistent Asthma

K.M. Beeh

Poster Board # A35

Date: Sunday, May 19
Poster Viewing: 10:45 a.m. - 12:30 p.m. ETTiotropium Is Effective In
Patients With Severe
Asthma Without Evidence
Of COPD

D. Halpin

Poster Board # B124

Date: Monday, May 20
Poster Viewing: 10:45 a.m. - 12:30 p.m. ETTiotropium Decreases The
Risk Of Exacerbations In
Patients With Symptomatic
Asthma Regardless Of
Baseline Characteristics


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... N.C. , Aug. 28, 2015  Delays ... research projects can slow down the decision-making process, ... is, therefore, absolutely critical for biopharmaceutical companies to ... research approval process for quicker and more meaningful ... by Best Practices, LLC, nearly three-quarters of benchmarked ...
(Date:8/28/2015)... Research and Markets ... the "12th Annual Report and Survey of ... their offering. The 2015 12th Annual ... Production is the most recent study of biotherapeutic ... future capacity and production. The report contains the ...
(Date:8/28/2015)... 28, 2015 Research ... of the "Investigation Report on China,s Insulin ... Developed by Novo Nordisk, insulin aspart ... important drug for the treatment of diabetes. Compared ... acting insulin analog, starts working fast and reports ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... 2011 CeNeRx BioPharma, Inc., a clinical-stage company developing ... nervous system (CNS), today announced FDA approval of its ... for CXB909, a novel agent that has demonstrated utility ... is a small molecule, orally active agent that enhances ...
... 9, 2011 Concentric Medical, Inc. today announced that the ... RE vascularization of large V essel O ... and at Capital Health in Trenton, New Jersey. Oregon Health ... Capital Health was first to use the Trevo device. TREVO ...
Cached Medicine Technology:CeNeRx Announces FDA IND Approval for its Neuroprotective Agent in Chemotherapy-Induced Neuropathy and Results From First Human Study 2CeNeRx Announces FDA IND Approval for its Neuroprotective Agent in Chemotherapy-Induced Neuropathy and Results From First Human Study 3Concentric Medical Announces First Patients Enrolled In TREVO 2 Clinical Trial 2Concentric Medical Announces First Patients Enrolled In TREVO 2 Clinical Trial 3
(Date:8/29/2015)... ... , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of Policy ... present an educational program titled “Asbestos and Your Health.” , The two and one ... at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA 19002. ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau ... shipping costs. , “Before, a threshold of $49.00 was required to qualify for free ... qualify for free standard shipping for customers regardless of the item’s selling price.” , ...
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Day at the Zoo to celebrate children helping children, a thank you to ... throughout West Ohio have contributed to the United Methodist initiative to end malaria ...
(Date:8/28/2015)... Church, VA (PRWEB) , ... ... ... Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and Best ... Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally renowned ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5
... Rival JoAnne,s Bed & Back; Merger Sets Up Healthy ... Largest Company Owned Back Retail Chain, LORTON, Va., ... focus on home and workplace back wellness created an,ergonomic ... Bed & Back. Healthy Back,s 18 stores and ecommerce ...
... This release is,being sent in a social media format, by ... the NIH., News:, * A new study being ... (Abstract #4020), may change treatment practice,in about 25 percent of ... to the way colorectal cancers will be staged., * ...
... sufferers gain benefit from calcitriol, an oral form , , FRIDAY, ... cut the risk of death for people with moderate to ... study suggests. , During a two-year study of more ... form of activated vitamin D, had their overall risk of ...
... Million for Life-threatening,Disease, BETHESDA, Md., May 16 ... for cystic fibrosis this weekend -- May 17 ... largest national CF,fund-raiser, the Cystic Fibrosis Foundation announced ... Month. Cystic fibrosis is a,life-threatening genetic disease that ...
... who would benefit most from chemo after surgery, study says ... 15 genes may help determine which patients with early-stage non-small ... the most from chemotherapy, a new study shows. , ... with less aggressive forms of the cancer who would be ...
... Millions of Children Still in Danger, NEW YORK, ... The,Advertising Council today announced a partnership to distribute and ... by A-List,celebrities, including Ben Stiller, Nicole Ritchie, Joel Madden, ... help survivors of the,Myanmar cyclone. The Ad Council is ...
Cached Medicine News:Health News:The Back Wars Come to a Close 2Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3
... 6 is an enzyme immunoassay (EIA) test ... various specific nuclear antigens (SS-A, SS-B, RNP/Sm, ... is used as an aid in the ... connective tissue disease (MCTD), Sjgren's syndrome and ...
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
The PalmSAT® 2500 series are small, yet versatile digital pulse oximeters for accurate assessment of blood oxygen saturation and pulse rate. Choose alarm or non-alarm versions for your portable ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: